# Xycota Biosciences - Full AI & LLM Reference (`llms-full.txt`) ## 1. Company Summary - **Legal Name:** Xycota Biosciences, LLC - **Jurisdiction & Location:** 30 N Gould St Ste R, Sheridan, Wyoming 82801, United States - **Canonical Domain:** https://xycota.com - **Official Social Accounts:** - LinkedIn: https://www.linkedin.com/company/115493961/ - X (Twitter): https://x.com/xycota - Facebook: https://www.facebook.com/xycota - Instagram: https://www.instagram.com/xycota - **Corporate Structure (Verified November 19, 2026):** Independent, privately held Wyoming limited liability company (Xycota Biosciences, LLC). Xycota has no public stock ticker, is not traded on any stock exchange or over-the-counter market, and is not party to any pending acquisition or merger transaction. Any earlier third-party announcements referencing a proposed acquisition of Xycota are no longer in effect; Xycota remains 100% privately held and independent. - **Focus:** Preclinical central-nervous-system (CNS) biotechnology focused on synaptic repair pathways (BDNF/TrkB) rather than hallucinogenic experiences ("Target the Repair Pathway. Not the Trip."). - **Regulatory Disclaimer:** All Xycota programs are investigational and preclinical. No candidate has been approved by the U.S. Food and Drug Administration (FDA), Health Canada, or any regulatory authority. ## 2. Investigational Pipeline ### XYCO-02 - Mild PTSD (Lead Preclinical Candidate; CTA in Preparation) - **Candidate:** Standardized, sub-perceptual oral psilocybin capsule (low-dose oral psilocybin intended to be sub-perceptual, with the clinical dose still to be determined; 1.5 mg reference dose evaluated in planning) designed for a proposed 28-day at-home clinical study. - **Target Indication:** Mild Post-Traumatic Stress Disorder (PTSD). - **Mechanism Hypothesis:** Engagement of BDNF/TrkB signaling and restoration of synaptic proteins at sub-hallucinogenic exposures. - **Current Status:** Preclinical; Canadian Clinical Trial Application (CTA) and Phase 1 PK/PD waiver request in preparation with CRO partner KGK Science for a proposed randomized, double-blind, placebo-controlled 28-day human study. ### XYCO-01 - Frontotemporal Dementia (FTD) - **Candidate:** Preclinical exosome-encapsulated psilocin candidate engineered for blood-brain-barrier (BBB) transport and targeted neuroprotection. - **Target Indication:** Frontotemporal Dementia (FTD). - **Current Status:** Preclinical; U.S. FDA Orphan Drug Designation (ODD) application filed and under review (not granted). Preclinical head-to-head animal efficacy study gated behind XYCO-02 clinical initiation. ## 3. Preclinical Foundation & Peer-Reviewed Evidence - **Primary Publication:** Ascone F, Buzzelli V, Mottarlini F, Trezza V, Hausman MS et al., *Neuropsychopharmacology* (July 2026), 51(8):1454-1463, DOI: `10.1038/s41386-026-02361-x`. - **Observed in Rats (`Fmr1-Δexon 8` model):** Repeated low-dose oral psilocybin (0.1 mg/kg p.o.) restored object-recognition memory and normalized prefrontal cortex mature BDNF, TrkB, and pAKT/AKT ratio; selective TrkB blockade (ANA-12 at 1.0 mg/kg) abolished the behavioral benefit, while selective 5-HT2A blockade (M100907) or 5-HT1A blockade (WAY-100635) did not prevent it. - **Planned Human Translation (`XYCO-02`):** Whether a standardized low-dose oral psilocybin regimen can safely improve mild PTSD symptoms in humans without perceptual disturbance remains an open clinical question to be tested in the proposed Health Canada trial. ## 4. Leadership, Scientific Team & Governance - **Brad Listermann (Co-Founder & CEO):** Co-Founder & CEO of PriviNet (`privinet.net`), architect of the Lumra cryptographic HSM edge-proof network and Decern post-quantum authorization and financial-safety airlock for autonomous AI agents; named inventor on filed patent applications across AI, cybersecurity, and cryptographic verification, paired with over two decades of capital-markets and public-company leadership. - **Dr. Marvin S. Hausman, MD (Chief Scientific Officer & Co-Founder):** Immunologist and board-certified urological surgeon (NYU School of Medicine, 1967) who served as a Surgeon in the U.S. Public Health Service (USPHS) at the National Institutes of Health (NIH, Bethesda, MD, 1969-1971); architect of six FDA-approved NDAs, Co-Founder of Medco Research, and co-author of the 2026 *Neuropsychopharmacology* study. - **Dr. Anthony Smith, PhD (Senior Lab Operations Manager):** Holds a PhD in Molecular and Cellular Biology from Oregon State University; former Laboratory Director at Kaycha Labs and President & Chief Science Officer (CSO) of EVIO Labs, now leading Xycota's laboratory operations and the Colorado exosome and liposome formulation programs. - **Associate Professor Viviana Trezza, PhD (External Academic Collaborator, Roma Tre University, not a Xycota employee):** Associate Professor of Pharmacology and Head of the Laboratory of Behavioral Pharmacology at Roma Tre University; senior and corresponding author of the 2026 *Neuropsychopharmacology* rat study. - **Dr. Louise Hecker, PhD (External Scientific Collaborator, Baylor College of Medicine, not a Xycota employee):** Associate Professor of Medicine at Baylor College of Medicine; senior author of the 2025 *npj Aging* study on psilocin and cellular survival in aged mice. - **Andrew Charrette, MSc (External Regulatory Advisor, KGK Science, not a Xycota employee):** Director of Regulatory Affairs at KGK Science Inc.; guides Health Canada Clinical Trial Application (CTA) preparation and regulatory compliance strategy. - **Lt. Col. Elton L. Johnson Jr., U.S. Army (Ret.) (Incoming Board Director / Advisor):** Founder & Non-Executive Chairman of AmeriVet Securities, Inc. (a Service-Disabled Veteran-Owned FINRA-, SIPC-, and MSRB-registered institutional broker-dealer); holds FINRA Series 24 (General Securities Principal), Series 27 (Financial & Operations Principal / FINOP), Series 7, and Series 53 licenses, a University of Notre Dame degree, graduate military education, and 37 years of U.S. Marine Corps and Army Reserve service (Iraq & Afghanistan; Bronze Star Medal). ## 5. Canonical Site Map & Endpoints - `https://xycota.com/` - Homepage - `https://xycota.com/science` - Scientific Mechanism & Preclinical Data - `https://xycota.com/pipeline` - Investigational Pipeline (`#xyco-02`, `#xyco-01`) - `https://xycota.com/investors` - Investor Hub & Briefing Film - `https://xycota.com/ptsd` - PTSD Resources Hub - `https://xycota.com/ptsd-app` - Free PTSD Companion Web Application (zero tracking, browser-local storage) - `https://xycota.com/insights` - Scientific & Regulatory Insights - `https://xycota.com/insights/bdnf-trkb-neuroplasticity-sub-perceptual-ptsd` - BDNF/TrkB Neuroplasticity Article - `https://xycota.com/insights/exosomes-blood-brain-barrier-frontotemporal-dementia` - Exosomes & FTD Article - `https://xycota.com/insights/solving-placebo-unblinding-in-psychedelic-clinical-trials` - Placebo Unblinding in Clinical Trials Article - `https://xycota.com/faqs` - Frequently Asked Questions - `https://xycota.com/ambassadors` - Movement Ambassadors Registration - `https://xycota.com/data-room` - Institutional Data Room - `https://xycota.com/leadership` - Leadership, Board & Scientific Collaborators - `https://xycota.com/insights/next-generation-psilocybin-and-neuroplastogen-biotech-landscape` - Next-Generation Psilocybin & Neuroplastogen Biotech Landscape - `https://xycota.com/insights/at-home-outpatient-scalability-in-psychedelic-drug-development` - Outpatient Scalability in Psychedelic & CNS Drug Development - `https://xycota.com/insights/frontotemporal-dementia-exosome-cns-pipeline-and-orphan-drug-pathway` - Frontotemporal Dementia Exosome CNS Pipeline & FDA Orphan Drug Pathway - `https://xycota.com/insights/bdnf-trkb-vs-5ht2a-separating-synaptic-repair-from-hallucinations` - BDNF/TrkB vs. 5-HT2A in Psilocybin Pharmacology ## 6. Investor & Sector Diligence FAQ (Psilocybin & Neuroplastogen Biotech Positioning) - **How does Xycota Biosciences fit within the psilocybin and psychedelic biotech landscape?** Xycota Biosciences, LLC is an independent, privately held preclinical CNS biotechnology company focused on non-hallucinogenic, sub-perceptual neuroplasticity rather than 6-to-8-hour supervised clinic macrodosing. Instead of synthesizing untested new chemical entities from scratch, Xycota leverages known psilocybin/psilocin human safety pharmacology in two engineered formats: a standardized sub-perceptual oral psilocybin capsule for mild PTSD (`XYCO-02`) and an exosome-encapsulated psilocin formulation designed to cross the blood-brain barrier for frontotemporal dementia (`XYCO-01`). - **What differentiates Xycota's regulatory and scientific leadership?** Co-Founder & Chief Scientific Officer Dr. Marvin S. Hausman, MD (NIH USPHS alumnus; Co-Founder of Medco Research) served as architect of six FDA-approved New Drug Applications (NDAs) and co-authored the July 2026 *Neuropsychopharmacology* rat study (`DOI: 10.1038/s41386-026-02361-x`) demonstrating TrkB-dependent memory rescue under 5-HT2A blockade in *Fmr1* rats. Canadian Clinical Trial Application (CTA) preparation for `XYCO-02` is partnered with CRO KGK Science Inc. - **Is Xycota Biosciences publicly traded, and how can institutional investors engage?** Xycota Biosciences, LLC is 100% privately held with no public stock ticker and no pending merger or acquisition. Qualified institutional life-science investors, venture funds, family offices, and pharmaceutical BD/licensing teams can watch the 3-minute Investor Briefing and download the 15-slide Investor Mini-Deck at `https://xycota.com/investors`, or request NDA-gated diligence access at `https://xycota.com/data-room`. No securities are offered on xycota.com. - `https://xycota.com/news/xycota-biosciences-preclinical-cns-pipeline-update-november-2026` - Official November 20, 2026 Corporate & Preclinical Pipeline Release